In vitro drug susceptibility of 40 international reference rapidly growing mycobacteria to 20 antimicrobial agents

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 9, 2015, Pages 15423-15431

  Pang, Hui ^a,b,c   Li, Guilian ^b,c   Wan, Li ^c   Jiang, Yi ^b   Liu, Haican ^b   Zhao, Xiuqin ^b   Zhao, Zhongfu ^a   Wan, Kanglin ^b,c  

^a CHANGZHI MEDICAL COLLEGE   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c Central South University   (China)

Author keywords

Antimicrobial; Drug susceptibility; Minimum inhibitory concentration (MIC); Rapidly growing mycobacteria (RGM); Reference strains

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; CAPREOMYCIN; CEFOXITIN; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; ETHAMBUTOL; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MINOCYCLINE; MOXIFLOXACIN; OFLOXACIN; RIFAMPICIN; STREPTOMYCIN; SULFAMETHOXAZOLE; TIGECYCLINE; TOBRAMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM CULTURE; COLONY FORMING UNIT; DRUG SENSITIVITY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM; NONHUMAN;

EID: 84946600936     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A and Daley C. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
2. Jang MA, Koh WJ, Huh HJ, Kim SY, Jeon K, Ki CS and Lee NY. Distribution of nontuberculous mycobacteria by multigene sequence-based typing and clinical significance of isolated strains. J Clin Microbiol 2014; 52: 1207-1212.
3. Griffith DE. Mycobacterium abscessus subsp abscessus lung disease: 'trouble ahead, trouble behind'. F1000Prime Rep 2014; 6: 107.
4. Preece CL, Perry A, Gray B, Kenna DT, Jones AL, Cummings SP, Robb A, Thomas MF, Brodlie M, O'Brien CJ, Bourke SJ, Perry JD. A novel culture medium for isolation of rapidly-growing mycobacteria from the sputum of patients with cystic fibrosis. J Cyst Fibros 2015; [Epub ahead of print].
5. Gray TJ, Kong F, Jelfs P, Sintchenko V, Chen SC. Improved Identification of Rapidly Growing Mycobacteria by a 16S-23S Internal Transcrib-ed Spacer Region PCR and Capillary Gel Electrophoresis. PLoS One 2014; 9: e102290.
6. El Helou G, Viola GM, Hachem R, Han XY and Raad II. Rapidly growing mycobacterial bloodstream infections. Lancet Infect Dis 2013; 13: 166-74.
7. Behr MA and Falinkham JO III. Molecular epidemiology of nontuberculous mycobacteria. Future Microbiol 2009; 4: 1009-1020.
8. Hernández-Garduño E and Elwood RK. Increasing incidence of nontuberculous mycobacteria, Taiwan, 2000-2008. Emerg Infect Dis 2010; 16: 1047.
9. Bicmen C, Coskun M, Gunduz AT, Senol G, Cirak AK and Tibet G. Nontuberculous mycobacteria isolated from pulmonary specimens between 2004 and 2009: causative agent or not? New Microbio 2010; 33: 399-403.
10. Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardi-ae, and Other aerobic actinomycetes; Approved Standard Second Edition. CLSI Document 2011; M24-A2.
11. Barrera L, Cooreman E, de Dieu Iragena J, Drobniewski F, Duda P, Havelkova M, Hoffner S, Kam KM, Kim SJ, Labelle S, Lambregts K, Leimane V, Nunn P, Ramsay A, Raviglione M, Rich M, Ridderhof J, Rodrigues F, Rüsch-Gerdes S, Salfinger M, Scholten J, Selvakumar N, Shinnick T, Shul'gina M, Šķenders G, Sloutsky A, Small P, Van Deun A, Varaine F, Yagui M, Vincent V, Weyer K, Wright A, Zignol M. World Health Organization. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. WHO Document 2008.
12. Shahraki AH, Heidarieh P, Bostanabad SZ, Khosravi AD, Hashemzadeh M, Khandan S, Biranvand M, Schraufnagel DE and Mirsaeidi M. "Multidrug-resistant tuberculosis" may be nontuberculous mycobacteria. Eur J Intern Med 2015; 26: 279-84.
13. Li G, Lian LL, Wan L, Zhang J, Zhao X, Jiang Y, Zhao LL, Liu H and Wan K. Antimicrobial susceptibility of standard strains of nontuberculous mycobacteria by microplate Alamar Blue assay. PLoS One 2013; 8: e84065.
14. van Ingen J, van der Laan T, Dekhuijzen R, Boeree M and van Soolingen D. In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands. Int J Antimicrob Agents 2010; 35: 169-73.
15. Park S, Kim S, Park EM, Kim H, Kwon OJ, Chang CL, Lew WJ, Park YK and Koh WJ. In vitro antimicrobial susceptibility of Mycoba-cterium abscessus in Korea. J Korean Med Sci 2008; 23: 49-52.
16. Tang SS, Lye DC, Jureen R, Sng LH and Hsu LY. Rapidly growing mycobacteria in Singapore, 2006-2011. Clin Microbiol Infect 2015; 21: 236-241.
17. Broda A, Jebbari H, Beaton K, Mitchell S and Drobniewski F. Comparative drug resistance of Mycobacterium abscessus and M. chelonae isolates from patients with and without cystic fibrosis in the United Kingdom. J Clin Microbiol 2013; 51: 217-223.
18. Huang TS, Lee SS, Hsueh PR, Tsai HC, Chen YS, Wann SR, Leu HS, Ko WC, Yan JJ, Yuan SZ, Chang FY, Lu JJ, Wang JH, Wang HK and Liu YC. Antimicrobial resistance of rapidly growing mycobacteria in western Taiwan: SMART program 2002. J Formos Med Assoc 2008; 107: 281-287.
19. Huang CW, Chen JH, Hu ST, Huang WC, Lee YC, Huang CC and Shen GH. Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan. Int J Antimicrob Agents 2013; 41: 218-223.
20. Fernández-Roblas R, Martín-de-Hijas NZ, Fernández-Martínez AI, García-Almeida D, Gadea I and Esteban J. In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. Antimicrob Agents Chemother 2008; 52: 4184-4186.
21. Bastian S, Veziris N, Roux AL, Brossier F, Gaillard JL, Jarlier V and Cambau E. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm (41) and rrl sequencing. Antimicrob Agents Chemother 2011; 55: 775-781.
22. Tsai YK, Liou CH, Fung CP, Lin JC and Siu LK. Single or in combination antimicrobial resistance mechanisms of Klebsiella pneumoniae contribute to varied susceptibility to different carbapenems. PLoS One 2013; 8: e79640.
23. Howard ST. Recent progress towards understanding genetic variation in the Mycoba-cterium abscessus complex. Tuberculosis (Edinb) 2013; 93 Suppl: S15-20.
24. Lee SH, Yoo HK, Kim SH, Koh WJ, Kim CK, Park YK and Kim HJ. The drug resistance profile of Mycobacterium abscessus group strains from Korea. Ann Lab Med 2014; 34: 31-37.
25. Raiol T, Ribeiro GM, Maranhão AQ, Bocca AL, Silva-Pereira I, Junqueira-Kipnis AP, Brigido Mde M and Kipnis A. Complete genome sequence of Mycobacterium massiliense. J Bacteriol 2012; 194: 5455.
26. Gayathri R, Therese KL, Deepa P, Mangai S, Madhavan HN. Antibiotic susceptibility pattern of rapidly growing mycobacteria. J Postgrad Med 2010; 56: 76-78.
27. Sampaio JL. Prokaryotic taxonomy rules and nomenclature changes in the Mycobacterium chelonae-abscessus group. Future Microbiol 2010; 5: 1457.